CinCor Pharma Inc (CINC) Stock
CINC is no longer traded. CinCor Pharma was acquired by AstraZeneca (AZN) in February 2023.
Each CINC share was exchanged for $26.00 in cash plus a contingent value right of up to $10.00. Prices on this page are historical; the last trade was February 23, 2023 at $29.06.
See AstraZeneca (AZN) stock →CinCor Pharma stock price history
CINC final trading statistics
- Final close
- $29.06
- Final trading day
- Feb 23, 2023
- Market cap at delisting
- $1.27B
- Shares outstanding
- 43.76M
- Final 52-week range
- $10.53 – $43.15
- Avg. volume (final 3 mo.)
- 817,110
- All-time high (split-adj.)
- $38.94 · Aug 2022
- All-time low (split-adj.)
- $10.75 · Dec 2022
- Return since IPO
- +81.6%
- Beta
- —
- Book value / share
- $11.86
- Price / book
- 2.45
CinCor Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$50.4M | -$16.26 |
| FY2020 | $0.00 | -$22.3M | — |
| FY2019 | $0.00 | -$5.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About CinCor Pharma Inc
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc..
CinCor Pharma stock FAQ
What happened to CinCor Pharma stock?
CinCor Pharma was acquired by AstraZeneca (AZN) in February 2023. Shareholders received $26.00 in cash plus a contingent value right of up to $10.00 for each share. CINC stock stopped trading on the Nasdaq, with a final close of $29.06 on February 23, 2023.
What did CinCor Pharma shareholders receive?
Each CINC share was converted into $26.00 in cash plus a contingent value right of up to $10.00. The deal was valued at about $1.8 billion.
Is CINC stock still trading?
No. CINC was delisted from the Nasdaq in February 2023 and no longer trades on a U.S. exchange.
What was the last price of CINC stock?
CINC closed at $29.06 on its final trading day, February 23, 2023, for a market value of about $1.27B.
What were CinCor Pharma's revenue and earnings in its last full fiscal year?
CinCor Pharma reported revenue of $0.00 and net income of -$50.4M in fiscal 2021, its last full year as a public company.
When did CinCor Pharma go public?
CinCor Pharma Inc stock began trading on January 7, 2022.